Successful combined auxiliary partial liver and intestinal transplantation in two highly sensitized, cross‐match positive patients
Clinical Transplantation · 2023-03 · 37 (3)
DOI: 10.1111/ctr.14865 ↗At a glance
Journal article in Clinical Transplantation, published online on 2023-01-09. Written by Guosheng Wu and 7 co-authors. Institution: Intestinal Transplant Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Major MEDLINE topics: Kidney Transplantation. Cited 3 times so far (Crossref); 17 references. Funded by: National Natural Science Foundation of China.
Abstract (original language)
Introduction
Sensitization to human leukocyte antigen (HLA) creates an immunological barrier to intestinal transplantation (ITx). Current desensitization therapies are limited and ineffective in the most highly sensitized patients. A co‐transplanted whole liver transplant can protect a kidney, heart, or intestinal allograft from antibody‐mediated injury. Whether an auxiliary partial liver allograft provides effective protection for highly sensitized intestinal transplant recipients is unknown.
Methods
Two patients with strong HLA donor‐specific antibody at high titer against their deceased donors underwent combined auxiliary partial liver and ITx across a positive cross‐match. The left lateral lobes from the combined‐graft recipients and the right liver lobes from the deceased donors were transplanted as a domino procedure to other four patients.
Results
Two combined‐graft recipients have had an uneventful postoperative course without major complications at a 12‐ and 24‐month follow‐up, respectively. Intestinal graft function has been excellent with no evidence of humoral or cellular rejection. While a positive cross‐match turned negative, titers of donor‐specific HLA antibodies gradually declined over time after transplant. The left liver lobes procured from the combined‐graft recipients were successfully transplanted into two pediatric patients (age 1.9, 2.4 years) and the right lobes from two deceased donors were successfully transplanted into two adult patients. All transplant procedures went well, without post‐operative complications related to the splitting technique.
Conclusion
Our results indicate that an auxiliary liver transplant can effectively protect a co‐transplanted intestinal allograft against rejection and suggest that this combined procedure may serve as a useful therapeutic adjunct for a highly sensitized intestinal transplant candidate.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Intestinal Transplant Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
- Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
- Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
- Zhejiang University Cancer Center, Zhejiang University, Hangzhou, China.
Funding
- National Natural Science Foundation of China
Cite
APA
Wu, G., Liu, C., Ma, N., Zhou, X., Zhao, L., Zhang, Y., Zhang, W., & Liang, T. (2023). Successful combined auxiliary partial liver and intestinal transplantation in two highly sensitized, cross‐match positive patients. Clinical Transplantation, 37(3). https://doi.org/10.1111/ctr.14865
Vancouver
Wu G, Liu C, Ma N, Zhou X, Zhao L, Zhang Y, et al. Successful combined auxiliary partial liver and intestinal transplantation in two highly sensitized, cross‐match positive patients. Clinical Transplantation. 2023;37(3). doi:10.1111/ctr.14865
BibTeX
@article{Wu2023,
author = {Wu, Guosheng and Liu, Chaoxu and Ma, Nan and Zhou, Xile and Zhao, Long and Zhang, Yuntao and Zhang, Wentong and Liang, Tingbo},
title = {Successful combined auxiliary partial liver and intestinal transplantation in two highly sensitized, cross‐match positive patients},
journal = {Clinical Transplantation},
year = {2023},
volume = {37},
number = {3},
doi = {10.1111/ctr.14865}
}
EUVIMED